Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT ID: NCT00088556
Last Updated: 2012-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2004-08-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00077883
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
NCT00047801
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
NCT06929936
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00040638
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
NCT01902875
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triplet Combination of TLK286 Carboplatin & Paclitaxel
Experimental
TLK286
Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
carboplatin
AUC 6 mg/mL/min Once every 3 weeks
paclitaxel
200 mg/m² Once every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TLK286
Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
carboplatin
AUC 6 mg/mL/min Once every 3 weeks
paclitaxel
200 mg/m² Once every 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed non-small cell lung cancer (NSCLC)
* Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation)
* Measurable disease by RECIST
* ECOG status of 0-1
* Adequate liver and renal function
* Adequate bone marrow reserves
Exclusion Criteria
* Up to one prior adjuvant or neoadjuvant chemotherapy is allowed
* History of bone marrow transplantation or stem cell support
* Pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Telik
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bay Area Cancer Research Group
Concord, California, United States
East Bay Medical Oncology/Hematology Associates
Concord, California, United States
Southwest Cancer Care
Escondido, California, United States
Kaiser Permanente Medical Center
Hayward, California, United States
Southwest Cancer Care
Murrieta, California, United States
Kaiser Permanente Medical Center
Oakland, California, United States
Southwest Cancer Care
Poway, California, United States
Kaiser Permanente Medical Center
Sacramento, California, United States
Kaiser Permanente Medical Center
San Francisco, California, United States
Kaiser Permanente Medical Center
San Jose, California, United States
Kaiser Permanente Medical Center
Santa Clara, California, United States
Kaiser Permanente Medical Center
So. San Francisco, California, United States
Kaiser Permanente Medical Center
Vallejo, California, United States
Diablo Valley Oncology & Hematology Medical Group
Walnut Creek, California, United States
Kaiser Permanente Medical Center
Walnut Creek, California, United States
Citrus Hematology and Oncology
Crystal River, Florida, United States
Citrus Hematology and Oncology Center
Inverness, Florida, United States
Florida Wellcare Alliance, LC
Inverness, Florida, United States
Kansas City Cancer Center
Kansas City, Kansas, United States
Kansas City Cancer Center - Central Research Dept. Data Office & Drug Discovery Location
Lenexa, Kansas, United States
Kansas City Cancer Center
Overland Park, Kansas, United States
Department of Veterns Affairs - Overton Brooks VA Medical Center
Shreveport, Louisiana, United States
LSU Health Sciences Center
Shreveport, Louisiana, United States
University of Maryland, Baltimore University of Maryland Medical System-Greenebaum Cancer Center
Baltimore, Maryland, United States
Center for Cancer and Blood Disorders, P. C.
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Kansas City Cancer Center
Kansas City, Missouri, United States
Kansas City Cancer Center
Kansas City, Missouri, United States
Kansas City Cancer Center
Kansas City, Missouri, United States
Kansas City Cancer Center
Lee's Summit, Missouri, United States
St. John's Mercy Medical Center
St Louis, Missouri, United States
St. John's Mercy Hospital
Washington, Missouri, United States
Clinical Research Service
Scottsbluff, Nebraska, United States
Horizons West Medical Group
Scottsbluff, Nebraska, United States
Dakota Cancer Institute
Fargo, North Dakota, United States
Odyssey Research
Fargo, North Dakota, United States
Tennessee Oncology, PLLC
Clarksville, Tennessee, United States
Tennessee Oncology, PLLC
Franklin, Tennessee, United States
Tennessee Oncology, PLLC
Hermitage, Tennessee, United States
Tennessee Oncology, PLLC
Lebanon, Tennessee, United States
Tennessee Oncology, PLLC
Murfreesboro, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Tennessee Oncology, PLLC
Smyrna, Tennessee, United States
Texas Cancer Associates
Dallas, Texas, United States
Texas Cancer Associates
Plano, Texas, United States
Danville Hematology & Oncology, Inc.
Danville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TLK286.2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.